NCT04287855 is a Phase 2 clinical trial of Isatuximab in Multiple Myeloma in Relapse, sponsored by Poitiers University Hospital.

Who is sponsoring NCT04287855?

NCT04287855 is sponsored by Poitiers University Hospital.

What drugs are being tested in NCT04287855?

Interventions in NCT04287855: Isatuximab, Carfilzomib, Pomalidomide, Dexamethasone.

What condition does NCT04287855 study?

NCT04287855 studies Multiple Myeloma in Relapse, Multiple Myeloma, Refractory.

Is NCT04287855 still recruiting?

NCT04287855 is currently status unknown. Last updated 10 January 2023.

Last reviewed 2023-01-10 · How we verify

NCT04287855

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Multicenter Open Label Phase 2 Study of Isatuximab Plus Pomalidomide and Dexamethasone With Carfilzomib in Relapsed or Refractory Multiple Myeloma

Status unknown Phase 2 Last updated 10 January 2023

What this trial tests

Phase 2 trial testing Isatuximab in Multiple Myeloma in Relapse in 82 participants. Status unknown.

Timeline

28 August 2020

Primary endpoint
15 April 2025

15 April 2026

Quick facts

Lead sponsor	Poitiers University Hospital
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	82
Start date	28 August 2020
Primary completion	15 April 2025
Estimated completion	15 April 2026
Sites	1 location across France

Drugs / interventions tested

Isatuximab (isatuximab) — full drug profile →
Carfilzomib (carfilzomib) — full drug profile →
Pomalidomide — full drug profile →
Dexamethasone (dexamethasone) — full drug profile →

Conditions studied

Multiple Myeloma in Relapse — all drugs for Multiple Myeloma in Relapse →
Multiple Myeloma, Refractory — all drugs for Multiple Myeloma, Refractory →

Sponsor

Poitiers University Hospital

Who can join

18 and older, any sex, with Multiple Myeloma in Relapse or Multiple Myeloma, Refractory. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Study a quadruplet-based regimen with Minimal Residual Disease (MRD) 10-5 negative rate as primary end point in patients with early Relapsed or Refractory Multiple Myeloma. Therapeutic study, phase II, prospective, multicenter, open-label. The patients will be treated until progression. Each cycle of treatment lasts 28 days. Cycle 1 to 13 : treatment phase After cycle 13 : maintenance phase

Publications & conference data

7 peer-reviewed publications reference this trial (live from Europe PMC):

Harnessing natural killer cells for cancer immunotherapy: dispatching the first responders.
Maskalenko NA, Zhigarev D, Campbell KS. · · 2022 · cited 174× · PMID 35314852 · DOI 10.1038/s41573-022-00413-7
Minimal Residual Disease in Multiple Myeloma: Current Landscape and Future Applications With Immunotherapeutic Approaches.
Kostopoulos IV, Ntanasis-Stathopoulos I, Gavriatopoulou M, Tsitsilonis OE, et al · · 2020 · cited 42× · PMID 32537439 · DOI 10.3389/fonc.2020.00860
Ikaros Proteins in Tumor: Current Perspectives and New Developments.
Xia R, Cheng Y, Han X, Wei Y, et al · · 2021 · cited 12× · PMID 34950704 · DOI 10.3389/fmolb.2021.788440
Pomalidomide- and dexamethasone-based regimens in the treatment of refractory/relapsed multiple myeloma.
Fotiou D, Gavriatopoulou M, Terpos E, Dimopoulos MA. · · 2022 · cited 11× · PMID 35585966 · DOI 10.1177/20406207221090089
Monoclonal Antibodies: Leading Actors in the Relapsed/Refractory Multiple Myeloma Treatment.
Morè S, Petrucci MT, Corvatta L, Fazio F, et al · · 2020 · cited 6× · PMID 33260960 · DOI 10.3390/ph13120426
Monoclonal Antibodies in Relapsed-Refractory Multiple Myeloma.
Sorgiovanni I, Del Giudice ML, Galimberti S, Buda G. · · 2025 · cited 1× · PMID 40005960 · DOI 10.3390/ph18020145
Consensus Guidelines and Recommendations for the anti-CD38-based Therapy in Clinical Practice for Relapsed/Refractory Multiple Myeloma: From the Pan-Pacific Multiple Myeloma Working Group.
Chen W, Cai Z, Chim CS, Chng WJ, et al · · 2025 · PMID 40786241 · DOI 10.46989/001c.141401

Verify or expand the search:

Other trials of Isatuximab

Trials testing the same drug.

NCT07045909 — Efficacy and Safety of Anitocabtagene Autoleucel in Participants With Newly Diagnosed Multiple Myeloma (GEM-AnitoFIRST) · Phase 2 · recruiting
NCT05862766 — Isatuximab in Lung Transplant Recipients · EARLY_PHASE1 · withdrawn
NCT05922501 — Isatuximab, Bela Maf, Pom, and Dex in Relapsed/Refractory Multiple Myeloma · Phase 2 · recruiting
NCT06182774 — Fixed Duration vs Continuous Anti-CD38 Antibody Therapy Among Transplant Ineligible Older Adults With Newly-Diagnosed Mu · Phase 3 · recruiting
NCT06203912 — Donor Immune Cells (TGFbi NK Cells) and Isatuximab for the Treatment of Relapsed or Refractory Multiple Myeloma · Phase 1 · active not recruiting

Other recruiting trials for Multiple Myeloma in Relapse

Currently open trials in the same condition.

NCT07096778 — Inobrodib, Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma · Phase 2 · recruiting
NCT06822972 — HCMT/MM2401: Ph2 Study of Selinexor + Bispecific Antibody for RRMM · Phase 2 · recruiting
NCT07032129 — Sequential CAR-T Cells Targeting BCMA/GPRC5D in Patients With Relapsed/ Refractory Multiple Myeloma · Phase 1, PHASE2 · recruiting
NCT07248176 — Universal CAR-T Cell Therapy for MM · NA · recruiting
NCT06846905 — Cost-utility Analysis of Ambulatory Dose Escalation of Bispecific Antibodies in Multiple Myeloma. · recruiting

Other Poitiers University Hospital trials

Trials by the same sponsor.

NCT07350291 — Evaluation of the Diagnostic Capabilities of Saliva Samples From Pediatric Patients, Promoting Active Involvement of the · NA · not yet recruiting
NCT07411651 — Confirmation of the Link Between Endocrine Disruptors Exposure and Breast Cancer and Identification of Biological Respon · NA · not yet recruiting
NCT07463963 — Relevance of the Urine Bacterial Culture Performed Before TransUrethral Resection of the Bladder for Post-operative Febr · NA · not yet recruiting
NCT07475442 — Prognostic Factors of Hospitalization for Patients Aged 75 and Over in Emergency Department in France - Monocentric Retr · not yet recruiting
NCT07412717 — The Efficacy of Combining Music Intervention With Nicotine Replacement Therapy to Reduce Smoking Craving, Among Healthca · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04287855 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Poitiers University Hospital
Last refreshed: 10 January 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04287855.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing